|
Tumor Microenvironment in Cancer Progression
|
ZIA BC 011332
|
$474,811
|
$189,924
|
Kaplan, Rosandra
|
CCR (NCI)
|
|
Translational Research in Breast Cancer (SPORE)
|
5P50CA186784-04
|
$2,300,000
|
$138,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Tissue-specific tumor suppressor effects of p53
|
3R01CA200256-03S1
|
$78,178
|
$39,089
|
MANFREDI, JAMES
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
Tissue-specific tumor suppressor effects of p53
|
5R01CA200256-03
|
$432,908
|
$216,454
|
MANFREDI, JAMES
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
Therapeutic Targeting of Malignant Glioma Stem Cells
|
5R35CA197725-04
|
$916,993
|
$458,497
|
LESNIAK, MACIEJ
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
The Role of the miRNA Cluster at 14q32 in Lipid Regulation and Renal Cancer Biology
|
1R03CA212696-01A1
|
$74,750
|
$74,750
|
NANJUNDAN, MEERA
|
UNIVERSITY OF SOUTH FLORIDA
|
|
The role of Dclk1 in the initiation of colorectal cancer
|
1R01CA214017-01A1
|
$338,550
|
$111,722
|
HOUCHEN, COURTNEY
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
|
The Antigen Targeting Core
|
ZIC BC 011030
|
$225,010
|
$112,505
|
Parkhurst, Maria
|
CCR (NCI)
|
|
TGFbeta Blockade in MART TCR-Engineered T Cell Melanoma Immunotherapy in Man
|
5R01CA164333-05
|
$352,335
|
$176,168
|
KOYA, RICHARD
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Telomere Biology
|
ZIA BC 011519
|
$1,268,391
|
$25,368
|
Cooper, Julia
|
CCR (NCI)
|
|
TCR Gene Transfer for Treating HCV-Associated Malignancies
|
5F30CA180731-03
|
$49,044
|
$49,044
|
SPEAR, TIMOTHY
|
LOYOLA UNIVERSITY CHICAGO
|
|
Targeting melanoma hypoxia with lactic acid bacterium L. lactis
|
1R21CA210202-01A1
|
$200,970
|
$200,970
|
GOMEZ-GUTIERREZ, JORGE
|
UNIVERSITY OF LOUISVILLE
|
|
Targeting epigenetic regulators using bacterial macromolecule delivery
|
5R01CA188382-04
|
$308,407
|
$308,407
|
FORBES, NEIL
|
UNIVERSITY OF MASSACHUSETTS AMHERST
|
|
Targeting CXCR4 and microRNA as Therapy for Chondrosarcoma
|
5R01CA166089-05
|
$280,000
|
$280,000
|
TEREK, RICHARD
|
RHODE ISLAND HOSPITAL
|
|
Targeted therapy of B cell malignances with CAR-T cells of defined composition
|
5R01CA136551-09
|
$560,424
|
$280,212
|
RIDDELL, STANLEY
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Targeted Delivery of Brain Penetrating DNA Nanoparticles to Brain Tumors
|
5R01CA204968-02
|
$512,053
|
$512,053
|
HANES, JUSTIN
|
JOHNS HOPKINS UNIVERSITY
|
|
T-cell receptor gene therapy for human papillomavirus-positive cancers
|
ZIA BC 011479
|
$671,060
|
$503,295
|
Hinrichs, Christian
|
CCR (NCI)
|
|
Surgery Branch Cell Prep Core
|
ZIC BC 010905
|
$933,290
|
$466,645
|
Wunderlich, John
|
CCR (NCI)
|
|
Stem Cell Gene Therapy Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patient
|
5U01CA183012-04
|
$312,304
|
$156,152
|
ZAIA, JOHN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
SPORE: Developing New Rationale, Personalized Medicine for Lung Cancer
|
5P50CA070907-19
|
$2,299,998
|
$460,000
|
MINNA, JOHN
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
SPORE: Brain Tumore SPORE Grant
|
5P50CA097257-15
|
$2,300,000
|
$115,000
|
BERGER, MITCHEL
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
SPORE in Skin Cancer
|
5P50CA174523-04
|
$2,300,000
|
$92,000
|
HERLYN, MEENHARD
|
WISTAR INSTITUTE
|
|
SPORE in Prostate Cancer
|
5P50CA058236-22
|
$1,993,426
|
$398,685
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
SPORE in Cervical Cancer
|
5P50CA098252-14
|
$2,300,000
|
$299,000
|
WU, TZYY-CHOOU
|
JOHNS HOPKINS UNIVERSITY
|
|
Significance of Inhibiting Long Non-coding RNAs in Advanced Breast Cancer
|
1R01CA218025-01
|
$376,105
|
$124,115
|
LIN, CHUNRU
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Role of the Long Non-coding RNA PVT1 in Cancer
|
7R01CA200643-02
|
$446,063
|
$446,063
|
BAGCHI, ANINDYA
|
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST
|
|
Role of microRNAs in the regulation of CML stem cell self renewal and survival
|
5R01CA163800-06
|
$264,526
|
$79,358
|
PERROTTI, DANILO
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
RNA Therapeutics for Targeted Treatment of Colon Cancer
|
5R01CA186100-04
|
$341,702
|
$341,702
|
GUO, BIN
|
UNIVERSITY OF HOUSTON
|
|
Retroviral Replicating Vector-mediated Gene Therapy for Ovarian Cancer
|
1R01CA213119-01A1
|
$504,040
|
$504,040
|
KASAHARA, NORIYUKI
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
Research Training Program in Surgical Oncology
|
3T32CA091078-15S1
|
$4,777
|
$478
|
KENNEDY, GREGORY
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Reprogramming Tumor-Associated Macrophages in PDAC with MicroRNA Nano-Vectors
|
1R21CA213114-01A1
|
$170,738
|
$170,738
|
AMIJI, MANSOOR
|
NORTHEASTERN UNIVERSITY
|
|
Reporter Gene Technologies for Integrated Cancer Diagnostics
|
5R01CA082214-17
|
$375,250
|
$93,813
|
GAMBHIR, SANJIV
|
STANFORD UNIVERSITY
|
|
Regulatory Pathways and Role of VPF/VEGF in Renal Cancer
|
5R01CA078383-19
|
$334,519
|
$334,519
|
MUKHOPADHYAY, DEBABRATA
|
MAYO CLINIC JACKSONVILLE
|
|
Regulation of MDM2 auto-ubiquitination and molecular targeting
|
5R01CA123490-10
|
$251,191
|
$62,798
|
ZHOU, MUXIANG
|
EMORY UNIVERSITY
|
|
Provectors for treatment of ovarian cancer
|
5R01CA207497-02
|
$352,623
|
$352,623
|
SUH, JUNGHAE
|
RICE UNIVERSITY
|
|
Potential therapeutic implications of targeting miR-150 in acute myeloid leukemia
|
5R01CA182528-05
|
$336,114
|
$336,114
|
CHEN, JIANJUN
|
UNIVERSITY OF CINCINNATI
|
|
Polymeric Nanoparticles for siRNA Delivery to Bone Marrow Endothelium to Disrupt Tumor Cell Adhesion and Bone Metastasis Formation In Vivo
|
3F32CA200351-02S1
|
$1,678
|
$1,678
|
MITCHELL, MICHAEL
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
|
Polymeric Nanoparticles for siRNA Delivery to Bone Marrow Endothelium to Disrupt Tumor Cell Adhesion and Bone Metastasis Formation In Vivo
|
5F32CA200351-03
|
$57,066
|
$57,066
|
MITCHELL, MICHAEL
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
|
PATTERNS OF r AAV VECTOR INSERTION ASSOCIATED WITH LIVER TUMORS IN A MOUSE MODEL
|
5R01CA172713-05
|
$303,988
|
$303,988
|
FU, HAIYAN
|
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
|
|
PATTERNS OF r AAV VECTOR INSERTION ASSOCIATED WITH LIVER TUMORS IN A MOUSE MODEL
|
3R01CA172713-04S1
|
$25,683
|
$25,683
|
MCCARTY, DOUGLAS
|
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
|
|
Overcoming Temozolomide Resistance using MGMT-targeting Spherical Nucleic Acids
|
5F30CA174058-05
|
$49,044
|
$49,044
|
SITA, TIMOTHY
|
NORTHWESTERN UNIVERSITY
|
|
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
|
1R21CA216678-01
|
$254,475
|
$127,238
|
BRADLEY, LINDA
|
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST
|
|
Ovarian cancer gene therapy using HPV pseudovirion
|
5R01CA183040-04
|
$336,150
|
$336,150
|
WU, TZYY-CHOOU
|
JOHNS HOPKINS UNIVERSITY
|
|
Optimizing Cancer Immunotherapy Safety and Efficacy using Genome Editing
|
1K99CA218870-01
|
$143,370
|
$143,370
|
KLEINSTIVER, BENJAMIN
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Optimization of a clinical stage nanoparticle drug delivery platform
|
5R44CA186410-03
|
$998,609
|
$499,305
|
BROWN, BOB
|
DICERNA PHARMACEUTICALS, INC.
|
|
Optimal DNA Brain-Penetrating Nanoparticle (DNA-BPN) Formulation for Glioblastoma (GBM) Treatment
|
5F31CA210610-02
|
$44,044
|
$44,044
|
NEGRON, KARINA
|
JOHNS HOPKINS UNIVERSITY
|
|
Novel targeted adenovirus
|
1R01CA211096-01A1
|
$348,844
|
$348,844
|
CURIEL, DAVID
|
WASHINGTON UNIVERSITY
|
|
Novel Nanoparticle Therapy for Pancreatic Cancer
|
5R01CA167535-05
|
$313,134
|
$313,134
|
MATTERS, GAIL
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
|
Novel combined immunotherapeutic strategies for glioma: using pet dogs as a large animal spontaneous model
|
1U01CA224160-01
|
$1,632,775
|
$816,388
|
Pluhar, Grace
|
UNIVERSITY OF MINNESOTA
|
|
Next Generation Oncolytic Adenovirus for Advanced Pancreatic Cancer Treatment
|
5R01CA168448-05
|
$315,400
|
$315,400
|
YAMAMOTO, MASATO
|
UNIVERSITY OF MINNESOTA
|
Total relevant funding to Gene Therapy for this search: $35,689,813
|